Clinical trial
OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial
NCT02104661 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial
- Lead sponsor
- Queen Mary University of London
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2014
- Completion date
- January 31, 2018
- Enrollment
- 30 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.